NCT01570296View on ClinicalTrials.gov

A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 3, 2011

Primary Completion Date

February 22, 2016

Study Completion Date

December 17, 2018

Conditions
Non-Small Cell Lung CancerSolid Tumors
Interventions
DRUG

Gefitinib and BKM120

Dose escalation study of gefitinib and BKM120 with expansion cohort

Trial Locations (1)

169610

National Cancer Centre Singapore, Singapore

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

National Cancer Centre, Singapore

OTHER

NCT01570296 - A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR | Biotech Hunter | Biotech Hunter